SI2200431T1 - Sestave in metode za zdravljenje raka - Google Patents

Sestave in metode za zdravljenje raka

Info

Publication number
SI2200431T1
SI2200431T1 SI200831655A SI200831655A SI2200431T1 SI 2200431 T1 SI2200431 T1 SI 2200431T1 SI 200831655 A SI200831655 A SI 200831655A SI 200831655 A SI200831655 A SI 200831655A SI 2200431 T1 SI2200431 T1 SI 2200431T1
Authority
SI
Slovenia
Prior art keywords
methods
cancer treatment
novel compositions
compositions
novel
Prior art date
Application number
SI200831655A
Other languages
English (en)
Slovenian (sl)
Inventor
Chiang Jia Li
Keith Mikule
Youzhi Li
Original Assignee
Boston Biomedical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical, Inc. filed Critical Boston Biomedical, Inc.
Publication of SI2200431T1 publication Critical patent/SI2200431T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
SI200831655A 2007-09-10 2008-09-10 Sestave in metode za zdravljenje raka SI2200431T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97114407P 2007-09-10 2007-09-10
US1337207P 2007-12-13 2007-12-13
EP08830633.7A EP2200431B1 (en) 2007-09-10 2008-09-10 Novel compositions and methods for cancer treatment
PCT/US2008/075906 WO2009036101A1 (en) 2007-09-10 2008-09-10 Novel compositions and methods for cancer treatment

Publications (1)

Publication Number Publication Date
SI2200431T1 true SI2200431T1 (sl) 2016-10-28

Family

ID=40452461

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200831655A SI2200431T1 (sl) 2007-09-10 2008-09-10 Sestave in metode za zdravljenje raka
SI200831606A SI2190429T1 (sl) 2007-09-10 2008-09-10 Nova skupina inhibitorjev poti stat3 in inhibitorjev poti matičnih celic raka
SI200831626A SI2194987T1 (sl) 2007-09-10 2008-09-10 Novi inhibitorji poti stat3 in inhibitorji matičnih celic raka

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI200831606A SI2190429T1 (sl) 2007-09-10 2008-09-10 Nova skupina inhibitorjev poti stat3 in inhibitorjev poti matičnih celic raka
SI200831626A SI2194987T1 (sl) 2007-09-10 2008-09-10 Novi inhibitorji poti stat3 in inhibitorji matičnih celic raka

Country Status (14)

Country Link
US (12) US8877803B2 (enExample)
EP (6) EP2190429B1 (enExample)
JP (16) JP5872160B2 (enExample)
CN (6) CN101854930B (enExample)
CA (4) CA2736564A1 (enExample)
CY (3) CY1117604T1 (enExample)
DK (4) DK2190429T3 (enExample)
ES (3) ES2569215T3 (enExample)
HR (3) HRP20160625T1 (enExample)
HU (3) HUE027443T2 (enExample)
PL (4) PL3067054T3 (enExample)
PT (2) PT2194987T (enExample)
SI (3) SI2200431T1 (enExample)
WO (3) WO2009036099A1 (enExample)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
EP2190429B1 (en) * 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009062199A1 (en) * 2007-11-09 2009-05-14 Fox Chase Cancer Center EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
US20130331294A1 (en) 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
ES2521676T3 (es) 2008-07-08 2014-11-13 Board Of Regents, The University Of Texas System Nuevos agentes inhibidores de la proliferación y de la activación de transductores de señales y activadores de la transcripción (STATS)
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
WO2010065444A1 (en) 2008-12-01 2010-06-10 University Of Central Florida Research Foundation, Inc. Drug composition cytotoxic for pancreatic cancer cells
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
CN101897979B (zh) * 2009-05-27 2012-08-22 上海市计划生育科学研究所 治疗前列腺疾病的靶向药物
WO2011069141A2 (en) 2009-12-04 2011-06-09 Board Of Regents, The University Of Texas System Interferon therapies in combination with blockade of stat3 activation
JP5794922B2 (ja) * 2009-12-28 2015-10-14 一般社団法人ファルマバレープロジェクト支援機構 １，３，４−オキサジアゾール−２−カルボキサミド化合物
US20110275577A1 (en) * 2010-01-08 2011-11-10 Moleculin, Llc Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs
CN102781316B (zh) 2010-03-01 2016-07-06 陶制药有限责任公司 癌症诊断和成像
AU2015218436B9 (en) * 2010-03-19 2017-03-09 Boston Biomedical, Inc. Novel Methods For Targeting Cancer Stem Cells
CN104016951B (zh) * 2010-03-19 2016-07-13 北京强新生物科技有限公司 靶向癌症干细胞的化合物和组合物
DK2547205T3 (da) * 2010-03-19 2024-05-27 1Globe Biomedical Co Ltd Hidtil ukendte fremgangsmåder til målretning mod cancerstamceller
NZ602328A (en) * 2010-03-19 2014-11-28 Boston Biomedical Inc Novel compounds and compositions for targeting cancer stem cells
WO2011130677A1 (en) * 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibitors of cancer stem cells
US20110301194A1 (en) * 2010-06-02 2011-12-08 Arqule, Inc. Method for Determining Treatment Efficacy
US8871802B2 (en) 2010-08-24 2014-10-28 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Naphthoquinones for disease therapies
EP2617435A4 (en) * 2010-09-16 2014-03-12 Univ Osaka THERAPEUTICS AND PROPHYLACTIC AGENTS FOR COMPOSITIONS OF AUTOIMMUNE DISEASES, INFLAMMATORY DISEASES, ALLERGIC DISEASES AND ORGAN TRANSPLANTS
US20130252956A1 (en) * 2010-11-22 2013-09-26 Howard Kallender Methods of treating cancer
CN103260647A (zh) * 2010-11-30 2013-08-21 伦敦健康科学中心研究公司 用于治疗心脏病的egfr拮抗剂
WO2012078982A2 (en) * 2010-12-09 2012-06-14 The Ohio State University Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells
CN103402993A (zh) * 2011-03-04 2013-11-20 舟山海中洲新生药业有限公司 用于疾病治疗的4，9-二羟基-萘并[2,3-b] 呋喃新型酯
KR20120130658A (ko) * 2011-05-23 2012-12-03 주식회사 파멥신 펩타이드가 융합된 이중표적항체 및 그 용도
CN103717214A (zh) * 2011-06-06 2014-04-09 阿克比治疗有限公司 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物
EP2755674A4 (en) * 2011-09-12 2015-04-08 Tau Therapeutics Llc ANTAGONISTS OF PRODUCTS OF THE HS-459642-UNIGEN CLUSTER TO AVOID PROLIFERATION, DEVELOPMENT, OR DIFFERENTIATION OF STEM CELLS WITH CANCER STEM CELLS
EP2776586B1 (en) * 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
JP2015506990A (ja) * 2012-02-17 2015-03-05 ゾウシャン ハイジョンジョウ シンシェン ファーマシューティカルズ カンパニー リミテッドＺｈｏｕｓｈａｎ Ｈａｉｚｈｏｎｇｚｈｏｕ Ｘｉｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． ４，９−ジヒドロキシ−ナフト［２，３−ｂ］フラン脂肪族酸エステルの誘導体の水性ナノ粒子懸濁液を調製する方法
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN103705926A (zh) * 2012-10-08 2014-04-09 贾力 预防原发性肿瘤在手术切除后再转移的药用组合物
DE102013003107A1 (de) 2013-02-25 2014-09-11 Thomas Rühl Naphthofurandione mit einer 1-Bromalkylgruppe oder einer 1-Hydroxyalkylgruppe in 2-Position und einer Alkylgruppe in 3-Position zum Furanring-Sauerstoff und Verfahren zu deren Herstellung
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
US20160030384A1 (en) * 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
AU2014261788B2 (en) * 2013-04-29 2019-07-11 Nantes Université Targeting O-acetylated GD2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells Cancer
US10745489B2 (en) 2013-04-29 2020-08-18 Ogd2 Pharma Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells cancer
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2016009655A (es) 2014-01-27 2016-11-09 Boston Biomedical Inc Metodos novedosos para el tratamiento del cancer.
CN106163284A (zh) * 2014-02-07 2016-11-23 北京强新生物科技有限公司 3‑取代的羰基萘并[2,3‑b]呋喃衍生物或其药学上可接受的盐
WO2015120436A2 (en) 2014-02-10 2015-08-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stat3 phosphorylation during graft-versus-host disease
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
EP3122884B1 (en) * 2014-03-26 2019-12-25 Tocagen Inc. A retroviral vector having immune-stimulating activity
WO2015164870A1 (en) 2014-04-25 2015-10-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gamma-aa-peptide stat3/dna inhibitors and methods of use
WO2015171985A1 (en) * 2014-05-09 2015-11-12 The Brigham And Women's Hospital, Inc. Treatment of igg-immune complex-mediated organ damage
EP3153508B1 (en) 2014-06-09 2020-03-18 Kyoto Pharmaceutical Industries, Ltd. Naphthofuran derivatives for use as anticancer agents
JP6626085B2 (ja) * 2014-07-15 2019-12-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 骨髄由来抑制細胞の抑制及び免疫チェックポイント阻害の方法
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20160066490A (ko) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
EP3242881B1 (en) 2015-01-08 2020-04-29 The United States of America, as represented by The Secretary, Department of Health and Human Services Furoquinolinediones as inhibitors of tdp2
US10183925B2 (en) 2015-03-27 2019-01-22 Boston Biomedical, Inc. Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer
CN104693279A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 关于信号传导及转录激活因子抑制多肽及其应用
CN104725480A (zh) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 一种信号传导及转录激活因子抑制多肽及其应用
CN104693280A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 信号传导及转录激活因子抑制多肽及其应用
JP2018511643A (ja) 2015-04-17 2018-04-26 ボストン バイオメディカル， インコーポレイテッド 癌を治療するための方法
KR20170137833A (ko) * 2015-04-17 2017-12-13 보스톤 바이오메디칼, 인크. 암의 치료 방법
WO2016168857A1 (en) * 2015-04-17 2016-10-20 Boston Biomedical, Inc. Methods for treating cancer
KR20170141716A (ko) * 2015-04-27 2017-12-26 보스톤 바이오메디칼, 인크. Stat3 경로 저해제 및 카이나제 저해제를 사용하여 암을 치료하는 방법
CN107835687A (zh) * 2015-05-14 2018-03-23 努卡那有限公司 癌症治疗
WO2016185333A1 (en) * 2015-05-15 2016-11-24 Novartis Ag Methods for treating egfr mutant cancers
WO2016196935A1 (en) * 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
US10329267B2 (en) 2015-07-17 2019-06-25 Sumitomo Dainippon Pharma Co., Ltd. Method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2017023866A1 (en) * 2015-07-31 2017-02-09 Boston Biomedical, Inc. Method of targeting stat3 and other non-druggable proteins
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
PH12018500691B1 (en) 2015-10-05 2022-08-10 NuCana plc Combination therapy
AU2017205478A1 (en) * 2016-01-07 2018-06-28 Swadesh K. Das A method of modulating survival and stemness of cancer stem cells by MDA-9/Syntenin (SDCBP)
WO2017132049A1 (en) 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
US11434229B2 (en) * 2016-03-01 2022-09-06 Academia Sinica 4,9-dioxo-4,9-dihydronaphtho[2,3-b]furan-3-carboxamide derivatives and uses thereof for treating proliferative diseases and infectious diseases
US10295527B2 (en) 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
US11946927B2 (en) 2016-03-14 2024-04-02 Musidora Biotechnology Llc Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
JP2017171640A (ja) * 2016-03-25 2017-09-28 学校法人兵庫医科大学 癌の治療システム
WO2017164379A1 (ja) * 2016-03-25 2017-09-28 大日本住友製薬株式会社 ２－アルキルカルボニルナフト［２，３－ｂ］フラン－４，９－ジオンの関連物質の製造方法、及びその関連物質
CN105837541A (zh) * 2016-04-23 2016-08-10 何淑琼 磷酸苯丙哌林的药物组合物及其在生物医药中的应用
CN105906595A (zh) * 2016-04-23 2016-08-31 陈斌 丙酸倍氯米松的药物组合物及其在生物医药中的应用
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2018005444A2 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
CN106380456B (zh) * 2016-08-29 2019-03-26 中南大学 一种合成苯并呋喃萘醌衍生物的方法
WO2018096401A1 (en) 2016-11-22 2018-05-31 Hitoshi Ban New naphtho[2,3-b]furan derivatives
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
CA3045306A1 (en) * 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
MX2019006326A (es) * 2016-11-30 2019-07-12 Tyme Inc Derivados de tirosina y composiciones que los comprenden.
WO2018133838A1 (zh) * 2017-01-22 2018-07-26 江苏恒瑞医药股份有限公司 Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
CN110753546B (zh) 2017-04-17 2023-11-10 耶鲁大学 治疗或预防急性肺损伤的化合物、组合物和方法
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
EP3635410A4 (en) * 2017-06-04 2021-03-10 Rappaport Family Institute for Research in the Medical Sciences PROCEDURE FOR PREDICTING PERSONALIZED RESPONSE TO CANCER TREATMENT USING IMMUNE CHECKPOINT INHIBITORS AND KITS
JP7387177B2 (ja) * 2017-07-20 2023-11-28 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ パルス磁場勾配を使用する悪性癌細胞の標的化浸透圧溶解
CN111295368A (zh) 2017-09-22 2020-06-16 大日本住友制药株式会社 化学活化型水溶性前药
US20200369607A1 (en) * 2017-11-16 2020-11-26 Tyrnovo Ltd. Combinations of irs/stat3 dual modulators and anti pd-1/pd-l1 antibodies for treating cancer
EP3501511A1 (en) * 2017-12-22 2019-06-26 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Means for preventing and treating brain metastasis
JP7336386B2 (ja) * 2017-12-28 2023-08-31 株式会社カネカ 多能性幹細胞凝集抑制剤
CN107973788B (zh) * 2018-01-09 2021-07-09 沈阳药科大学 Bbi608衍生物及其制备与用途
ES2941771T3 (es) * 2018-03-20 2023-05-25 Sumitomo Pharma Co Ltd Derivados de dihidrocromeno
PL3773537T3 (pl) * 2018-04-19 2022-05-23 Tvardi Therapeutics, Inc. Inhibitory stat3
WO2019232214A1 (en) 2018-05-31 2019-12-05 Boston Biomedical, Inc. Methods of using napabucasin
US20220008409A1 (en) * 2018-09-18 2022-01-13 Kabushiki Kaisha Yakult Honsha Cancer combination therapy using quinoline carboxamide derivative
MX2021004151A (es) * 2018-10-12 2021-09-08 1Globe Biomedical Co Ltd Nueva solución de combinación para el tratamiento contra cáncer refractario a la quimioterapia.
CN109288846A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat3抑制剂晶型a联合用药物组合物
CN109200044A (zh) * 2018-10-31 2019-01-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂酒石酸盐联合用药物组合物
CN109331004A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂甲磺酸盐A晶型联合用药物组合物
CN109172563A (zh) * 2018-10-31 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种噻吨酮类紫杉醇和stat3抑制剂联合用药物组合物
CN109966297A (zh) * 2018-10-31 2019-07-05 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat抑制剂马来酸盐晶型i联合用药物组合物
CN109846888A (zh) * 2018-10-31 2019-06-07 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和吲哚类stat3抑制剂联合用药物组合物
CN109200052A (zh) * 2018-10-31 2019-01-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和芴酮类stat3抑制剂联合用药物组合物
CN109288845A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种咔唑类stat抑制剂马来酸盐晶型ii联合用药物组合物及其制备方法
CN109288847A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat抑制剂甲磺酸盐晶型p联合用药物组合物
CN109223758A (zh) * 2018-10-31 2019-01-18 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和芴类stat3抑制剂联合用药物组合物
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
CA3136230A1 (en) * 2019-04-09 2020-10-15 Generos Biopharma Ltd. Pharmaceutical combination of pimozide and methotrexate and use thereof
US11564913B2 (en) 2019-05-03 2023-01-31 Children's Hospital Medical Center Compositions and methods for treating cancer
CN110218198B (zh) * 2019-05-22 2022-06-28 广州中医药大学(广州中医药研究院) 一种萘醌并三氮唑核心骨架衍生物化合物及其制备方法和应用
JPWO2020251015A1 (enExample) * 2019-06-14 2020-12-17
JP7287929B2 (ja) * 2019-09-25 2023-06-06 住友ファーマ株式会社 ジヒドロクロメン誘導体を含有する医薬
KR20220098759A (ko) * 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
JP2023502252A (ja) * 2019-11-20 2023-01-23 イエール ユニバーシティ 虚血再灌流傷害および／または肺傷害を処置するための化合物、組成物および方法
US20230013636A1 (en) * 2019-12-05 2023-01-19 Board Of Regents, The University Of Texas System Exosomes-based therapy for liver fibrosis and other diseases with fibrosis
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN115135326B (zh) * 2020-03-16 2024-09-13 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途
JP7788400B2 (ja) * 2020-05-11 2025-12-18 パーデュー・リサーチ・ファウンデーション 連続フロー条件下でのロムスチンのスケールアップ合成
CN114286684B (zh) * 2020-07-27 2024-01-05 华中科技大学 与stat3相关的疾病的预防和/或治疗
WO2022216930A1 (en) * 2021-04-08 2022-10-13 Virginia Commonwealth University Novel mda-9 antagonist with anti-metastatic potential
CN114591306B (zh) * 2022-03-03 2024-03-01 陕西中医药大学 一种1,2,4-三唑环的1,4萘醌类stat3抑制剂及其应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472133A (en) * 1947-03-20 1949-06-07 Du Pont Thiophanthraquinone derivatives
SU1049490A1 (ru) 1982-05-18 1983-10-23 Ордена Трудового Красного Знамени Институт Химии Ан Мсср (3 @ ,9 @ ,9 @ )-6,6,9 @ -Триметилтранспергидронафто(2,1- @ )фуран,в качестве душистого компонента парфюмерной композиции
JPS616149A (ja) 1984-06-20 1986-01-11 Mitsubishi Electric Corp 無機絶縁体の製法
JPS63196576A (ja) * 1987-02-10 1988-08-15 Tetsuo Ikegawa フラルナフトキノン誘導体と制癌剤及びその製造方法
EP0309926A3 (de) 1987-09-29 1990-12-05 Siemens Aktiengesellschaft Verfahren zur Herstellung vollparametrisierbarer Schaltungen in integrierter Schaltkreistechnik
JPH01121284A (ja) 1987-11-06 1989-05-12 Eisai Co Ltd トコフェロール　ｎ，ｎ−ジアルキルアミノアルキルカルボン酸エステルの胆汁酸塩
EP0402192A1 (fr) 1989-05-31 1990-12-12 BODET, Jean Augustin Article en carton ou matière analogue et procédé de fabrication
JPH04139177A (ja) 1989-12-28 1992-05-13 Dainippon Ink & Chem Inc フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
DE69131874T2 (de) * 1990-07-10 2000-06-15 Canon K.K., Tokio/Tokyo Elektrophotographisches empfindliches Element
JP2942015B2 (ja) * 1990-07-10 1999-08-30 キヤノン株式会社 電子写真感光体およびそれを用いた電子写真装置
TW252136B (enExample) 1992-10-08 1995-07-21 Ciba Geigy
JP3598168B2 (ja) 1996-03-18 2004-12-08 独立行政法人 科学技術振興機構 抗ウイルス剤
JPH1121284A (ja) 1997-06-30 1999-01-26 Kotobuki:Kk フラノナフトキノン誘導体及びこれを含有する医薬
JPH1165141A (ja) * 1997-08-11 1999-03-05 Canon Inc 電子写真感光体、該電子写真感光体を有するプロセスカ−トリッジ及び電子写真装置
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
JP2003525862A (ja) 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害
EP1169021B1 (en) * 1999-04-01 2009-09-16 Hana Biosciences, Inc. Compositions and methods for treating lymphoma
US6482943B1 (en) * 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
PT1206436E (pt) 1999-08-02 2004-12-31 Hoffmann La Roche Retinoides para o tratamento de enfisema
JP2001097860A (ja) 1999-09-29 2001-04-10 Japan Science & Technology Corp 抗薬剤耐性菌剤と抗クラミジア剤
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
KR20010100194A (ko) 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US7998947B2 (en) * 2001-03-28 2011-08-16 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
GB0117696D0 (en) 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
AU2002357012A1 (en) 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
JP2005517637A (ja) 2001-11-29 2005-06-16 セラコス・インコーポレイテッド 体外フォトフォレーシスおよび／またはアポプトーシス細胞による一定の被験体を前処理するための方法
NZ535349A (en) * 2002-03-08 2007-01-26 Signal Pharm Inc JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
DE60307701T2 (de) 2002-03-15 2007-10-11 Natimmune A/S Mannose-Bindungsprotein enthaltende pharmazeutische Zusammensetzungen
AU2002336473A1 (en) 2002-09-10 2004-04-30 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
WO2004026253A2 (en) * 2002-09-17 2004-04-01 Arqule, Inc. Novel lapacho compounds and methods of use thereof
TWI323662B (en) 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
IS6633A (is) * 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2535762A1 (en) 2003-08-13 2005-03-17 University Of South Florida Methods for inhibiting tumor cell proliferation
US20050049207A1 (en) * 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
WO2005033048A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
EP1706133B1 (en) 2003-12-02 2010-10-06 Cleveland Clinic Foundation Methods of protecting against radiation using flagellin
EP2487156B1 (en) * 2003-12-11 2014-07-16 Board Of Regents The University Of Texas System Compounds for treatment of cell proliferative diseases
DE10359828A1 (de) * 2003-12-12 2005-07-28 Zoser B. Dr.Rer.Nat. Salama CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe
WO2005110477A2 (en) * 2004-04-09 2005-11-24 University Of South Florida Combination therapies for cancer and proliferative angiopathies
JP2004224802A (ja) * 2004-04-21 2004-08-12 Japan Science & Technology Agency 抗菌剤
AU2005270102A1 (en) * 2004-07-02 2006-02-09 Icos Corporation Compounds useful for inhibiting Chk1
KR20070046175A (ko) * 2004-08-18 2007-05-02 아스트라제네카 아베 선택된 융합 복소환 및 이의 용도
CA2587276A1 (en) * 2004-11-08 2006-05-18 Baxter International Inc. Nanoparticulate compositions of tubulin inhibitor compounds
RU2007123675A (ru) * 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
US7807662B2 (en) * 2004-12-23 2010-10-05 University Of South Florida Platinum IV complex inhibitor
JP2008535785A (ja) * 2005-02-25 2008-09-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｓｔａｔ３の小分子阻害剤およびその使用
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2006290871A (ja) 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
US20060252073A1 (en) 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
JPWO2006126505A1 (ja) 2005-05-26 2008-12-25 国立大学法人 東京大学 Ｓｔａｔ機能阻害剤およびその応用
US8133692B2 (en) * 2005-07-20 2012-03-13 University Of South Florida Methods of predicting responsiveness to chemotherapeutic agents and selecting treatments
BRPI0617364A2 (pt) 2005-10-13 2011-07-26 Orchid Res Lab Ltd compostos heterocÍclicos como inibidores de pstat3/il-6
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
JP2007145680A (ja) 2005-11-30 2007-06-14 Idemitsu Kosan Co Ltd 水素発生材料および水素発生方法
WO2007074347A1 (en) * 2005-12-24 2007-07-05 Biotica Technology Ltd. 21-deoxymacbecin analogues useful as antitumor agents
US20090012075A1 (en) * 2006-01-12 2009-01-08 Miller Thomas A Fluorinated Arylamide Derivatives
KR101478164B1 (ko) * 2006-02-09 2014-12-31 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
WO2007100640A2 (en) * 2006-02-21 2007-09-07 The Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
WO2007095753A1 (en) * 2006-02-24 2007-08-30 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic) - 1h-phenanthro [9,10-d] imidazoles
WO2007115269A2 (en) * 2006-03-31 2007-10-11 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
US20070238770A1 (en) 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
US8828451B2 (en) 2006-10-04 2014-09-09 University Of South Florida Akt sensitization of cancer cells
WO2008077062A2 (en) * 2006-12-19 2008-06-26 Board Of Regents, The University Of Texas System Suppression of stat3 reactivation after src kinase inhibition to treat cancer
JP4077863B1 (ja) 2007-05-31 2008-04-23 タヒボジャパン株式会社 抗癌活性を有する光学活性２−（１−ヒドロキシエチル）−５−ヒドロキシナフト［２，３−ｂ］フラン−４，９−ジオンの製法
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2009060282A2 (en) 2007-11-06 2009-05-14 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
DK2547205T3 (da) 2010-03-19 2024-05-27 1Globe Biomedical Co Ltd Hidtil ukendte fremgangsmåder til målretning mod cancerstamceller
CN104016951B (zh) 2010-03-19 2016-07-13 北京强新生物科技有限公司 靶向癌症干细胞的化合物和组合物
NZ602328A (en) 2010-03-19 2014-11-28 Boston Biomedical Inc Novel compounds and compositions for targeting cancer stem cells
AU2015218436B9 (en) 2010-03-19 2017-03-09 Boston Biomedical, Inc. Novel Methods For Targeting Cancer Stem Cells
CN103402993A (zh) 2011-03-04 2013-11-20 舟山海中洲新生药业有限公司 用于疾病治疗的4，9-二羟基-萘并[2,3-b] 呋喃新型酯
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
JP2018511643A (ja) 2015-04-17 2018-04-26 ボストン バイオメディカル， インコーポレイテッド 癌を治療するための方法
WO2016168857A1 (en) 2015-04-17 2016-10-20 Boston Biomedical, Inc. Methods for treating cancer
KR20170137833A (ko) 2015-04-17 2017-12-13 보스톤 바이오메디칼, 인크. 암의 치료 방법
KR20170141716A (ko) 2015-04-27 2017-12-26 보스톤 바이오메디칼, 인크. Stat3 경로 저해제 및 카이나제 저해제를 사용하여 암을 치료하는 방법
WO2016196935A1 (en) 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
WO2017132049A1 (en) 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法

Also Published As

Publication number Publication date
CA2911990C (en) 2018-03-20
CA2736532A1 (en) 2009-03-19
WO2009036099A1 (en) 2009-03-19
US20110112180A1 (en) 2011-05-12
US9745278B2 (en) 2017-08-29
JP2016034976A (ja) 2016-03-17
CN101854802A (zh) 2010-10-06
CN103288787A (zh) 2013-09-11
JP5688840B2 (ja) 2015-03-25
CN105963289B (zh) 2021-02-26
HUE027657T2 (en) 2016-11-28
JP5701603B2 (ja) 2015-04-15
US20150018410A1 (en) 2015-01-15
HRP20160949T1 (hr) 2016-10-07
CN104586832B (zh) 2018-02-16
WO2009036101A1 (en) 2009-03-19
EP3058941A1 (en) 2016-08-24
CN101854937B (zh) 2013-03-27
CA2736564A1 (en) 2009-03-19
EP3050566B1 (en) 2018-11-28
CN101854930A (zh) 2010-10-06
EP3050566A2 (en) 2016-08-03
CN105963289A (zh) 2016-09-28
JP2014231522A (ja) 2014-12-11
US20120252763A1 (en) 2012-10-04
JP2018131464A (ja) 2018-08-23
ES2583010T3 (es) 2016-09-16
JP2010539095A (ja) 2010-12-16
SI2194987T1 (sl) 2016-10-28
CA2736532C (en) 2018-03-20
JP5925849B2 (ja) 2016-05-25
EP2194987A2 (en) 2010-06-16
JP2016065101A (ja) 2016-04-28
CY1117833T1 (el) 2017-05-17
EP2200431B1 (en) 2016-07-20
EP3058941B1 (en) 2019-05-22
JP2016147906A (ja) 2016-08-18
EP2194987B1 (en) 2016-05-18
US20170197932A1 (en) 2017-07-13
HK1148943A1 (en) 2011-09-23
ES2584904T3 (es) 2016-09-30
US20180030022A1 (en) 2018-02-01
US20100310503A1 (en) 2010-12-09
DK3050566T3 (en) 2019-03-11
JP2010539098A (ja) 2010-12-16
HUE029111T2 (en) 2017-02-28
PL3067054T3 (pl) 2021-10-04
JP2014221843A (ja) 2014-11-27
EP2200431A1 (en) 2010-06-30
WO2009036059A3 (en) 2009-07-02
CY1118476T1 (el) 2017-07-12
JP5872160B2 (ja) 2016-03-01
HUE027443T2 (en) 2016-10-28
EP2194987A4 (en) 2011-11-30
US20180030021A1 (en) 2018-02-01
EP2190429A4 (en) 2011-12-14
CA2736563A1 (en) 2009-03-19
CN101854930B (zh) 2016-05-04
PT2194987T (pt) 2016-08-05
US20210115006A1 (en) 2021-04-22
CY1117604T1 (el) 2017-04-26
DK2200431T3 (en) 2016-08-15
US8877803B2 (en) 2014-11-04
ES2569215T3 (es) 2016-05-09
HK1148906A1 (en) 2011-09-23
US20190263768A1 (en) 2019-08-29
PL2190429T3 (pl) 2016-09-30
US9732055B2 (en) 2017-08-15
EP2200431A4 (en) 2011-12-21
EP2190429A1 (en) 2010-06-02
PL2200431T3 (pl) 2017-01-31
EP3050566A3 (en) 2016-11-30
PL2194987T3 (pl) 2017-01-31
JP2016094465A (ja) 2016-05-26
JP5938072B2 (ja) 2016-06-22
CN104586832A (zh) 2015-05-06
JP6358659B2 (ja) 2018-07-18
US20190135773A1 (en) 2019-05-09
JP2020117547A (ja) 2020-08-06
SI2190429T1 (sl) 2016-10-28
EP3067054A1 (en) 2016-09-14
JP6106149B2 (ja) 2017-03-29
HRP20160430T1 (hr) 2016-05-20
US10851075B2 (en) 2020-12-01
CA2911990A1 (en) 2009-03-19
JP2019073560A (ja) 2019-05-16
JP6346628B2 (ja) 2018-06-20
US10377731B2 (en) 2019-08-13
EP3067054B1 (en) 2020-12-30
US9834532B2 (en) 2017-12-05
DK2194987T3 (en) 2016-08-15
HRP20160625T1 (hr) 2016-08-12
JP2010539097A (ja) 2010-12-16
CN101854937A (zh) 2010-10-06
HK1148942A1 (zh) 2011-09-23
US20210024482A1 (en) 2021-01-28
JP2020143135A (ja) 2020-09-10
WO2009036059A2 (en) 2009-03-19
JP2015034179A (ja) 2015-02-19
DK2190429T3 (en) 2016-05-30
US20200039948A1 (en) 2020-02-06
CN103288787B (zh) 2016-08-03
CN101854802B (zh) 2014-12-03
EP2190429B1 (en) 2016-04-20
JP6347795B2 (ja) 2018-06-27
PT2200431T (pt) 2016-08-03
JP2018076349A (ja) 2018-05-17
JP2015038151A (ja) 2015-02-26
CA2736563C (en) 2016-01-26

Similar Documents

Publication Publication Date Title
PL3067054T3 (pl) Nowe kompozycje i sposoby leczenia nowotworów
IL257681A (en) Methods and compositions for the treatment of cancer
PL2173379T3 (pl) Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
PL2155188T3 (pl) Sposoby i kompozycje do leczenia nawrotowego raka
PL2340042T3 (pl) Sposoby i kompozycje do leczenia raka
IL218987A0 (en) Methods and compositions for treating cancer
ZA201001811B (en) Seed treatment compositions and methods
ZA201001810B (en) Seed treatment compositions and methods
GB0807263D0 (en) Formulations for cancer treatment
IL214349A0 (en) Compositions and methods for the treatment of cancer
PL2187967T3 (pl) Sposoby i kompozycje do leczenia raka
EP2176406A4 (en) COMPOSITIONS AND METHOD FOR CANCER TREATMENT
WO2007081751A9 (en) Compositions and methods for the treatment of cancer
IL204945A0 (en) Compositions and methods for inhibiting tumor progression
EP2137213A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER
GB0707556D0 (en) Treatment for cancer
HUE054409T2 (hu) Új kompozíciók és eljárások rák kezelésére
SI3067054T1 (sl) Novi sestavki in postopki za zdravljenje raka
GB0611130D0 (en) Cancer treatment
GB0723503D0 (en) Cancer treatment
GB0700493D0 (en) Cancer treatment
GB0712513D0 (en) Treatment of cancer
AU2007904940A0 (en) Methods and compositions for treating gynecological cancer
GB0604741D0 (en) Cancer Treatment